Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

3.84USD
26 Oct 2020
Change (% chg)

-- (--)
Prev Close
$3.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,464,886
52-wk High
$6.28
52-wk Low
$1.38

Latest Key Developments (Source: Significant Developments)

BioCryst Pharmaceuticals Q2 Loss Per Share $0.24
Thursday, 6 Aug 2020 

Aug 6 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES.Q2 LOSS PER SHARE $0.24.Q2 REVENUE $2.9 MILLION VERSUS $1.4 MILLION.Q2 REVENUE ESTIMATE $2.3 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.EXPECTS FULL YEAR 2020 NET OPERATING CASH USE TO BE IN RANGE OF $150 TO $165 MILLION.SEES 2020 OPERATING EXPENSES TO BE IN RANGE OF $180 TO $195 MILLION.  Full Article

FDA Grants Fast Track Designation For BCX9930 In PNH
Monday, 3 Aug 2020 

Aug 3 (Reuters) - BioCryst Pharmaceuticals Inc ::FDA GRANTS FAST TRACK DESIGNATION FOR BCX9930 IN PNH.BIOCRYST PHARMACEUTICALS - LOOK FORWARD TO REGULATORY DISCUSSIONS LATER THIS YEAR ON CLINICAL TRIALS FOR BCX9930 IN NEPHROLOGY INDICATIONS.  Full Article

BioCryst Pharmaceuticals Reports Q1 Loss Per Share $0.24
Wednesday, 6 May 2020 

May 6 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES.Q1 LOSS PER SHARE $0.24.Q1 REVENUE $4.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $4.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.EXPECTS 2020 NET OPERATING CASH USE TO BE IN THE RANGE OF $125 TO $150 MILLION.  Full Article

Biocryst Pharmaceuticals Files For Mixed Shelf Of Up To $500 Mln
Friday, 24 Apr 2020 

April 24 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $500.0 MILLION - SEC FILING.  Full Article

BioCryst Reports Q4 Loss Per Share $0.02
Thursday, 5 Mar 2020 

March 5 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES.Q4 LOSS PER SHARE $0.02.Q4 REVENUE $39.7 MILLION VERSUS $2.7 MILLION.Q4 REVENUE ESTIMATE $9.9 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.EXPECTS FULL YEAR 2020 NET OPERATING CASH USE TO BE IN RANGE OF $125 TO $150 MILLION.BIOCRYST PHARMACEUTICALS - EXPECTS FULL YEAR 2020 OPERATING EXPENSES TO BE IN RANGE OF $135 TO $160 MILLION.  Full Article

FDA Accepts BioCryst's NDA For Oral, Once Daily Berotralstat To Prevent HAE Attacks
Tuesday, 18 Feb 2020 

Feb 18 (Reuters) - BioCryst Pharmaceuticals Inc ::FDA ACCEPTS BIOCRYST’S NDA FOR ORAL, ONCE DAILY BEROTRALSTAT (BCX7353) TO PREVENT HAE ATTACKS.BIOCRYST PHARMACEUTICALS INC - PDUFA DATE FOR NDA FOR ORAL, ONCE DAILY BEROTRALSTAT (BCX7353) TO PREVENT HAE ATTACKS IS DECEMBER 3, 2020.  Full Article

BioCryst Enters Securities Purchase Agreement With 667 LP And Baker Brothers Life Sciences LP
Wednesday, 20 Nov 2019 

Nov 20 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC - CO ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH 667, L.P. AND BAKER BROTHERS LIFE SCIENCES, L.P..BIOCRYST PHARMACEUTICALS - AGREED TO ISSUE AND SELL , IN OFFERING TO BUYERS, PRE-FUNDED WARRANTS UP TO 11.8 MILLION SHARES AT $1.69/SHARE.BIOCRYST PHARMACEUTICALS INC - UPON CLOSING OF OFFERING, CO EXPECTS TO RECEIVE PROCEEDS OF ABOUT $19.9 MILLION.  Full Article

Steven Cohen Reports A 6.1% Passive Stake In Biocryst Pharmaceuticals- SEC Filing
Wednesday, 20 Nov 2019 

Nov 19 (Reuters) - BioCryst Pharmaceuticals Inc ::STEVEN A. COHEN REPORTS A 6.1% PASSIVE STAKE IN BIOCRYST PHARMACEUTICALS, AS OF NOV. 18 - SEC FILING.  Full Article

BioCryst Prices Public Offering Of Common Stock
Thursday, 14 Nov 2019 

Nov 13 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PRICES PUBLIC OFFERING OF COMMON STOCK.BIOCRYST PHARMACEUTICALS INC- ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 37.9 MILLION SHARES, OFFERED AT PRICE OF $1.45 PER SHARE.  Full Article

BioCryst Commences Public Offering Of Common Stock
Wednesday, 13 Nov 2019 

Nov 12 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST COMMENCES PUBLIC OFFERING OF COMMON STOCK.BIOCRYST PHARMACEUTICALS INC - OFFERING TO SELL $55 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

BRIEF-Biocryst Announces Berotralstat Expanded Access Program For Patients With Hereditary Angioedema In United States

* BIOCRYST ANNOUNCES BEROTRALSTAT EXPANDED ACCESS PROGRAM FOR PATIENTS WITH HEREDITARY ANGIOEDEMA IN UNITED STATES Source text for Eikon: Further company coverage: